Dr. Scott Rocklage has a rich experience and educational equipment that helps him manage 5AM Ventures with swift excellence. He earned his first bachelors from the University of California before starting a doctorate degree in Chemistry from MIT. He also has a bachelors from Berkeley.
Before starting 5AM Ventures, Scott was the chief executive officer and chairman of Cubist Pharmaceuticals. He served Nycomed Salutar as a chief executive officer and president and administered Catalytica and Salutar in several top positions. Scott was the executive chairman of Ilypsa before its acquisition by Amgen and EntreMed and Miikana.
Scott started 5AM Ventures and deliberately branded it with that name to reflect the firm’s ambitions and values. The company helps innovative biotech companies fund their research projects with the end goal of alienating medical complications inflicting society.
He started out as a venture partner in 2004 and became the managing partner in 2004. He currently heads the life science sector and is responsible for managing the board meetings. He interacts directly with potential investors, scientists, business executives and physicians who influence the firm’s vision drafts and business moves.
Scott uses his more than three decade experience to apply a wealth of skillsets in all his endeavors. He marries his scientific inclination with his administration expertise to undertake promising projects and propel them to manifest the targeted goals.
As a 61 year old professional, Scott Rocklage serves as a council member of a couple of boards that share his firm’s attributes and visions. He is on the boards of Variation, Pulmatrix, WaveRx and Whitehead Institute board of associates. He sits as chairman on the councils of Rennovia, Kinestral and Cidara Therapeutics.
Scott’s uphill progression in his career is the primary effort of his focus and passion and also the collective work of carefully selecting his colleagues. He stresses on the need of surrounding himself with competent professionals who add his energy and fuel his vision. Read more: Scott Racklage | Bloomberg and Scott Racklage | Crunchbase
Scott’s core motivation of working with 5AM Ventures is to study the intricacies of cancer and the possible treatment solutions. Most of the firm’s projects support projects that concentrate on studying genome types and solutions that will serve every patients efficiently during therapy.
Scott has previously worked closely with Richard R. Schrock, a 2005 Nobel Prize Winner. He performed a multitude of his experiments in his lab and praises Richard for his ambitious streak and perceptive visions. Scott loves the book Good to Great and comments that it is an eye opener for anyone scaling through life.